BWC-0977 is under clinical development by Bugworks Research and currently in Phase I for Bacillus anthracis Infections. According to GlobalData, Phase I drugs for Bacillus anthracis Infections have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BWC-0977’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BWC-0977 overview

BWC-0977 is under development for the treatment of Gram-negative bacterial infections like Acinetobacter, Acinetobacter baumannii infections, Pseudomonas aeruginosa infections, Enterococcus faecium infections, Staphylococcus aureus infections, Campylobacter Bacillus anthracis infections, Klebsiella pneumoniae, Escherichia coli infections, Yersinia pestis Infections, Francisella tularensis Infections, Burkholderia pseudomallei Infections (Melioidosis), Burkholderia mallei Infections (Glanders) and Bacillus anthracis Infections. The therapeutic candidate is administered through intravenous and oral routes. The therapeutic candidate acts by targeting DNA gyrase and topoisomerase IV. It was under development for Gram-positive bacterial infections.

Bugworks Research overview

Bugworks Research (Bugworks) develops novel class of antibacterial agents and immunotherapies to treat infection and cancer patients with critical care needs. Bugworks is headquartered in Saratoga, California, the US.

For a complete picture of BWC-0977’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.